|
EP1777294A1
(en)
|
2005-10-20 |
2007-04-25 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
|
|
PT2529747T
(pt)
|
2005-12-02 |
2018-05-09 |
Icahn School Med Mount Sinai |
Vírus da doença de newcastle quiméricos que apresentam proteínas de superfície não nativas e suas utilizações
|
|
CA2690825C
(en)
|
2007-05-11 |
2019-02-12 |
Altor Bioscience Corporation |
Fusion molecules and il-15 variants
|
|
CN105017429B
(zh)
|
2010-09-21 |
2021-04-06 |
阿尔托生物科学有限公司 |
多聚体il-15可溶性融合分子与其制造与使用方法
|
|
US11053299B2
(en)
|
2010-09-21 |
2021-07-06 |
Immunity Bio, Inc. |
Superkine
|
|
EP2537933A1
(en)
|
2011-06-24 |
2012-12-26 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
An IL-15 and IL-15Ralpha sushi domain based immunocytokines
|
|
MD4655C1
(ro)
|
2013-03-14 |
2020-06-30 |
Icahn School Of Medicine At Mount Sinai |
Virusurile bolii de Newcastle şi utilizarea acestora
|
|
HK1220918A1
(zh)
|
2013-04-19 |
2017-05-19 |
赛腾制药 |
降低的血管渗漏综合征的细胞因子衍生治疗
|
|
US11273204B2
(en)
*
|
2013-08-08 |
2022-03-15 |
Cytune Pharma |
IL-15 and IL-15RAPLHA sushi domain based immunocytokines
|
|
EP3030262B1
(en)
*
|
2013-08-08 |
2019-10-09 |
Cytune Pharma |
Combined pharmaceutical composition
|
|
US20170000832A1
(en)
|
2014-02-27 |
2017-01-05 |
Viralytics Limited |
Combination method for treatment of cancer
|
|
EP2915569A1
(en)
|
2014-03-03 |
2015-09-09 |
Cytune Pharma |
IL-15/IL-15Ralpha based conjugates purification method
|
|
US10618963B2
(en)
|
2014-03-12 |
2020-04-14 |
Yeda Research And Development Co. Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
|
|
US9394365B1
(en)
|
2014-03-12 |
2016-07-19 |
Yeda Research And Development Co., Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
|
|
ES3040431T3
(en)
|
2014-03-12 |
2025-10-31 |
Yeda Res & Dev |
Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
|
|
US10519237B2
(en)
|
2014-03-12 |
2019-12-31 |
Yeda Research And Development Co. Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
|
|
EP3160498B1
(en)
*
|
2014-06-30 |
2021-10-06 |
Altor BioScience Corporation |
Il-15-based molecules and methods of use thereof
|
|
WO2016014565A2
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Treatment of cancer using humanized anti-bcma chimeric antigen receptor
|
|
JP6655061B2
(ja)
*
|
2014-07-29 |
2020-02-26 |
ノバルティス アーゲー |
状態を治療するためのｉｌ−１５およびｉｌ−１５ｒアルファヘテロ二量体用量増加レジメン
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
MX389663B
(es)
|
2014-10-14 |
2025-03-20 |
Novartis Ag |
Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas.
|
|
HUE052182T2
(hu)
*
|
2014-12-19 |
2021-04-28 |
Jiangsu Hengrui Medicine Co |
Interleukin 15 fehérjekomplex és annak felhasználása
|
|
DK3317301T3
(da)
|
2015-07-29 |
2021-06-28 |
Immutep Sas |
Kombinationsterapier omfattende antistofmolekyler mod lag-3
|
|
US20180222982A1
(en)
|
2015-07-29 |
2018-08-09 |
Novartis Ag |
Combination therapies comprising antibody molecules to pd-1
|
|
EP3878465A1
(en)
|
2015-07-29 |
2021-09-15 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
|
EP3359157A4
(en)
|
2015-10-06 |
2019-05-15 |
The Wistar Institute Of Anatomy And Biology |
METHOD AND COMPOSITIONS FOR THE TREATMENT OF METASTASIVE AND REFRACTORY CANCER DISEASES AND TUMORS
|
|
EP3389712B1
(en)
|
2015-12-17 |
2024-04-10 |
Novartis AG |
Antibody molecules to pd-1 and uses thereof
|
|
WO2017173367A2
(en)
|
2016-03-31 |
2017-10-05 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Extracellular vesicles, methods of making them, and methods of reducing liver uptake of extracellular vesicles
|
|
US11096965B2
(en)
|
2016-04-04 |
2021-08-24 |
The Regents Of The University Of California |
Compositions and methods related to polycytotoxic T cells
|
|
US20190117690A1
(en)
|
2016-04-06 |
2019-04-25 |
The University State Of America As Represented By The Secretary Of The Department Of Health And Hum |
Use of heterodimeric il-15 in adoptive cell transfer
|
|
WO2017180587A2
(en)
|
2016-04-11 |
2017-10-19 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
|
WO2017201352A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Mrna combination therapy for the treatment of cancer
|
|
CA3029813A1
(en)
|
2016-06-13 |
2017-12-21 |
Torque Therapeutics, Inc. |
Methods and compositions for promoting immune cell function
|
|
WO2018013855A2
(en)
*
|
2016-07-14 |
2018-01-18 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Il-15/il-15 receptor alpha treatment regimens and use with therapeutic vaccines
|
|
KR20240042177A
(ko)
|
2016-10-05 |
2024-04-01 |
유니버시티 오브 센트럴 플로리다 리서치 파운데이션, 인코포레이티드 |
Nk 세포 및 항-pdl1 암 요법과 관련된 방법 및 조성물
|
|
WO2018075989A1
(en)
|
2016-10-21 |
2018-04-26 |
Altor Bioscience Corporation |
Multimeric il-15-based molecules
|
|
AU2018208883B2
(en)
*
|
2017-01-20 |
2021-02-11 |
Novartis Ag |
Combination therapy for the treatment of cancer
|
|
EP3589308A1
(en)
*
|
2017-02-28 |
2020-01-08 |
Sanofi |
Therapeutic rna
|
|
US11629340B2
(en)
|
2017-03-03 |
2023-04-18 |
Obsidian Therapeutics, Inc. |
DHFR tunable protein regulation
|
|
US20190048055A1
(en)
*
|
2017-03-31 |
2019-02-14 |
Altor Bioscience Corporation |
Alt-803 in combination with anti-cd38 antibody for cancer therapies
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
JOP20190256A1
(ar)
|
2017-05-12 |
2019-10-28 |
Icahn School Med Mount Sinai |
فيروسات داء نيوكاسل واستخداماتها
|
|
WO2018217203A1
(en)
*
|
2017-05-25 |
2018-11-29 |
Oreilly Richard John |
Use of the il-15/il-15ra complex in the generation of antigen-specific t cells for adoptive immunotherapy
|
|
WO2018237173A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
AU2018287519B2
(en)
|
2017-06-22 |
2021-07-22 |
Novartis Ag |
IL-1beta binding antibodies for use in treating cancer
|
|
EP3641812A1
(en)
|
2017-06-22 |
2020-04-29 |
Novartis AG |
Antibody molecules to cd73 and uses thereof
|
|
WO2018235056A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
Il-1beta binding antibodies for use in treating cancer
|
|
AU2018292618A1
(en)
|
2017-06-27 |
2019-12-19 |
Novartis Ag |
Dosage regimens for anti-TIM-3 antibodies and uses thereof
|
|
KR20250025039A
(ko)
|
2017-07-20 |
2025-02-20 |
노파르티스 아게 |
항-lag-3 항체의 투여 요법 및 그의 용도
|
|
TWI810196B
(zh)
*
|
2017-07-25 |
2023-08-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
一種il-15蛋白質複合物醫藥組成物及其用途
|
|
KR20210032924A
(ko)
|
2017-09-05 |
2021-03-25 |
토크 테라퓨틱스, 인코포레이티드 |
치료용 단백질 조성물 및 그의 제조 및 사용 방법
|
|
TW201925782A
(zh)
|
2017-11-30 |
2019-07-01 |
瑞士商諾華公司 |
靶向bcma之嵌合抗原受體及其用途
|
|
EP3717008A1
(en)
|
2017-12-01 |
2020-10-07 |
Merus N.V. |
Use of bispecific antibody and il-15 for combination therapy
|
|
TWI825066B
(zh)
*
|
2018-02-01 |
2023-12-11 |
美商再生元醫藥公司 |
治療性單株抗體之品質屬性的定量及模型化
|
|
WO2019160956A1
(en)
|
2018-02-13 |
2019-08-22 |
Novartis Ag |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
|
TWI869346B
(zh)
|
2018-05-30 |
2025-01-11 |
瑞士商諾華公司 |
Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
|
|
US20210214459A1
(en)
|
2018-05-31 |
2021-07-15 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
TWI848951B
(zh)
|
2018-06-01 |
2024-07-21 |
瑞士商諾華公司 |
針對ｂｃｍａ之結合分子及其用途
|
|
AU2019284911A1
(en)
|
2018-06-13 |
2020-12-17 |
Novartis Ag |
BCMA chimeric antigen receptors and uses thereof
|
|
KR20210025525A
(ko)
*
|
2018-06-22 |
2021-03-09 |
카이트 파마 인코포레이티드 |
키메라 막횡단 단백질 및 그의 용도
|
|
KR20250130696A
(ko)
*
|
2018-06-22 |
2025-09-02 |
큐진 인크. |
신규한 인터루킨-15 (ｉｌ-15) 융합 단백질 및 이의 용도
|
|
US11634467B2
(en)
|
2018-06-22 |
2023-04-25 |
Cugene Inc. |
Cytokine-based bioactivatable drugs and methods of uses thereof
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
US12459980B2
(en)
|
2018-07-25 |
2025-11-04 |
AskGene Pharma, Inc. |
IL-21 prodrugs and methods of use thereof
|
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
|
US12391957B2
(en)
|
2018-08-17 |
2025-08-19 |
Icahn School Of Medicine At Mount Sinai |
Recombinant Newcastle disease viruses and uses thereof for the prevention of RSV disease or human metapneumovirus disease
|
|
ES3042082T3
(en)
|
2018-08-31 |
2025-11-18 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
WO2020128972A1
(en)
|
2018-12-20 |
2020-06-25 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
EP3898674A1
(en)
|
2018-12-21 |
2021-10-27 |
Novartis AG |
Use of il-1beta binding antibodies
|
|
EP3897613A1
(en)
|
2018-12-21 |
2021-10-27 |
Novartis AG |
Use of il-1beta binding antibodies
|
|
AU2019406840A1
(en)
|
2018-12-21 |
2021-06-03 |
Novartis Ag |
Use of IL-1 beta antibodies in the treatment or prevention of myelodysplastic syndrome
|
|
WO2020128637A1
(en)
|
2018-12-21 |
2020-06-25 |
Novartis Ag |
Use of il-1 binding antibodies in the treatment of a msi-h cancer
|
|
ES2982474T3
(es)
|
2019-02-15 |
2024-10-16 |
Novartis Ag |
Derivados de 3-(1-oxoisoindolin-2-il)piperidin-1,6-diona sustituidos y usos de estos
|
|
ES3032659T3
(en)
|
2019-02-15 |
2025-07-23 |
Novartis Ag |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
EP3725370A1
(en)
|
2019-04-19 |
2020-10-21 |
ImmunoBrain Checkpoint, Inc. |
Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
|
|
KR20220012296A
(ko)
|
2019-05-20 |
2022-02-03 |
싸이튠 파마 |
암 또는 감염성 질환 치료를 위한 IL-2/IL-15Rβγ 작용제 투여 요법
|
|
WO2020252264A1
(en)
*
|
2019-06-12 |
2020-12-17 |
AskGene Pharma, Inc. |
Novel il-15 prodrugs and methods of use thereof
|
|
WO2021050789A1
(en)
|
2019-09-10 |
2021-03-18 |
Obsidian Therapeutics, Inc. |
Ca2-il15 fusion proteins for tunable regulation
|
|
US20220348651A1
(en)
|
2019-09-18 |
2022-11-03 |
Novartis Ag |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
|
CN114786679A
(zh)
|
2019-10-21 |
2022-07-22 |
诺华股份有限公司 |
具有维奈托克和tim-3抑制剂的组合疗法
|
|
CN114786680A
(zh)
|
2019-10-21 |
2022-07-22 |
诺华股份有限公司 |
Tim-3抑制剂及其用途
|
|
CN115087464B
(zh)
*
|
2019-12-13 |
2025-02-25 |
科优基因公司 |
新型白介素-15(il-15)融合蛋白及其用途
|
|
US20210188933A1
(en)
*
|
2019-12-18 |
2021-06-24 |
Nantcell, Inc |
Methods of treating pancytopenia
|
|
MX2022007759A
(es)
|
2019-12-20 |
2022-07-19 |
Novartis Ag |
Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico.
|
|
EP4090335A1
(en)
|
2020-01-17 |
2022-11-23 |
Novartis AG |
Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
|
|
CA3168469A1
(en)
*
|
2020-02-05 |
2021-08-12 |
Novartis Ag |
Cho cell expressing il-15 heterodimers
|
|
MX2022015852A
(es)
|
2020-06-23 |
2023-01-24 |
Novartis Ag |
Regimen de dosificacion que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona.
|
|
EP4188549A1
(en)
|
2020-08-03 |
2023-06-07 |
Novartis AG |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
US20230321285A1
(en)
|
2020-08-31 |
2023-10-12 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
EP4204020A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
|
KR20230096047A
(ko)
|
2020-10-26 |
2023-06-29 |
싸이튠 파마 |
비흑색종 피부암 치료용 IL-2/IL-15Rβγ 작용제
|
|
US20230390361A1
(en)
|
2020-10-26 |
2023-12-07 |
Cytune Pharma |
Il-2/il-15r-beta-gamma agonist for treating squamous cell carcinoma
|
|
AU2021373366A1
(en)
|
2020-11-06 |
2023-06-01 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
CN117597355A
(zh)
|
2021-06-23 |
2024-02-23 |
赛腾制药 |
白细胞介素15变体
|
|
CA3225815A1
(en)
|
2021-08-13 |
2023-02-16 |
Cytune Pharma |
Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer
|
|
US20230151095A1
(en)
|
2021-11-12 |
2023-05-18 |
Xencor, Inc. |
Bispecific antibodies that bind to b7h3 and nkg2d
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
WO2024040132A2
(en)
|
2022-08-16 |
2024-02-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic |
Synergistic interactions for improved cancer treatment
|
|
WO2024102636A1
(en)
|
2022-11-07 |
2024-05-16 |
Xencor, Inc. |
Bispecific antibodies that bind to b7h3 and mica/b
|
|
WO2024215987A1
(en)
|
2023-04-14 |
2024-10-17 |
Sotio Biotech Inc. |
IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES
|
|
WO2024215989A1
(en)
|
2023-04-14 |
2024-10-17 |
Sotio Biotech Inc. |
ENGINEERED IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-2/IL-15 RECEPTOR βγ AGONISTS
|
|
US20250243279A1
(en)
|
2023-10-17 |
2025-07-31 |
Xencor, Inc. |
Bispecific antibodies that bind to nkp46 and mica/b
|